BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 16845439)

  • 1. Lasofoxifene: a new type of selective estrogen receptor modulator for the treatment of osteoporosis.
    Gennari L
    Drugs Today (Barc); 2006 Jun; 42(6):355-67. PubMed ID: 16845439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lasofoxifene, a new selective estrogen receptor modulator for the treatment of osteoporosis and vaginal atrophy.
    Gennari L
    Expert Opin Pharmacother; 2009 Sep; 10(13):2209-20. PubMed ID: 19640205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies].
    Maeda T; Ke HZ; Simmons H; Thompson D
    Clin Calcium; 2004 Oct; 14(10):85-93. PubMed ID: 15577137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development.
    Gennari L; Merlotti D; Valleggi F; Martini G; Nuti R
    Drugs Aging; 2007; 24(5):361-79. PubMed ID: 17503894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene.
    Gennari L; Merlotti D; Nuti R
    Clin Interv Aging; 2010 Feb; 5():19-29. PubMed ID: 20169039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lasofoxifene: a third-generation selective estrogen receptor modulator for the prevention and treatment of osteoporosis.
    Gennari L; Merlotti D; Martini G; Nuti R
    Expert Opin Investig Drugs; 2006 Sep; 15(9):1091-103. PubMed ID: 16916275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lasofoxifene: CP 336156, CP-336156.
    Drugs R D; 2005; 6(1):56-60. PubMed ID: 15801869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lasofoxifene: selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis.
    Peterson GM; Naunton M; Tichelaar LK; Gennari L
    Ann Pharmacother; 2011 Apr; 45(4):499-509. PubMed ID: 21467260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice.
    Maximov PY; Lee TM; Jordan VC
    Curr Clin Pharmacol; 2013 May; 8(2):135-55. PubMed ID: 23062036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats.
    Wang XN; Simmons HA; Salatto CT; Cosgrove PG; Thompson DD
    Menopause; 2006; 13(4):609-20. PubMed ID: 16837883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development.
    Pinkerton JV; Goldstein SR
    Menopause; 2010; 17(3):642-53. PubMed ID: 20107426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
    McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
    Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolution of selective estrogen receptor modulators in osteoporosis therapy.
    Hadji P
    Climacteric; 2012 Dec; 15(6):513-23. PubMed ID: 22853318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of SERMs for treatment in postmenopausal women.
    Pinkerton JV; Thomas S
    J Steroid Biochem Mol Biol; 2014 Jul; 142():142-54. PubMed ID: 24373794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective estrogen receptor modulators in clinical practice: a safety overview.
    Ellis AJ; Hendrick VM; Williams R; Komm BS
    Expert Opin Drug Saf; 2015 Jun; 14(6):921-34. PubMed ID: 25936229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Next generation selective estrogen receptor modulators].
    Chaki O
    Clin Calcium; 2006 Jan; 16(1):145-52. PubMed ID: 16397365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis.
    Lewiecki EM
    J Womens Health (Larchmt); 2009 Oct; 18(10):1615-26. PubMed ID: 19857095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lasofoxifene in osteoporosis and its place in therapy.
    Swan VJ; Hamilton CJ; Jamal SA
    Adv Ther; 2010 Dec; 27(12):917-32. PubMed ID: 21080249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective estrogen receptor modulators: the future in menopausal treatment.
    Palacios S
    Minerva Ginecol; 2011 Jun; 63(3):275-86. PubMed ID: 21654612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lasofoxifene (CP-336,156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat.
    Ke HZ; Qi H; Crawford DT; Chidsey-Frink KL; Simmons HA; Thompson DD
    Endocrinology; 2000 Apr; 141(4):1338-44. PubMed ID: 10746637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.